FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.

By
Matthew Solan, senior writer
Matthew Solan, senior writer
Matthew Solan, senior writer
May 14, 2026
6 min

Retinal Physician

Overview

The FDA is refining its regulatory approaches for retinal therapeutics, focusing on trial design and evidence requirements. Key initiatives include real-time clinical trials and expedited review pathways for breakthrough therapies.

Background

As retinal therapeutics evolve, understanding the FDA's regulatory landscape is crucial for ophthalmology sponsors and specialists. The agency's approach to clinical evidence and trial design is adapting to address the complexities of new treatments, particularly in rare and ultra-rare diseases. These updates are essential for ensuring timely access to innovative therapies for patients with significant unmet medical needs.

Data Highlights

No numerical data available in the source material.

Key Findings

The FDA acknowledges potential bias from sham injections in clinical trials but encourages strategies to minimize this bias.
AI tools are being used by the FDA for data collation, not as substitutes for scientific judgment in review decisions.
The Real-Time Clinical Trials program aims to provide near real-time access to clinical trial data for FDA reviewers.
The Commissioner’s National Priority Voucher Pilot Program could shorten review timelines for certain breakthrough therapies to as little as 2 months.
Single pivotal trials remain possible but must be exceptionally large and statistically robust to meet FDA evidentiary standards.
New initiatives for rare diseases include the Rare Disease Innovation Hub and guidance for individualized therapies targeting ultra-rare conditions.

Clinical Implications

Healthcare professionals should be aware of the evolving FDA guidelines that may impact clinical trial designs and regulatory submissions. Engaging with the FDA early in the trial design process is recommended to ensure alignment with regulatory expectations, especially for innovative therapies targeting rare diseases.

Conclusion

The FDA's updates on retinal trials and regulatory pathways highlight the agency's commitment to adapting its processes to facilitate the development of innovative therapies. These changes are vital for improving patient access to effective treatments in the rapidly advancing field of ophthalmology.